Article info
PDFNeurogastroenterology
Original article
A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D)
- Correspondence to Professor Robin Spiller, NIHR Nottingham Digestive Diseases Biomedical Research Unit, E Floor West Block, Queen's Medical Centre, University of Nottingham, Derby Road, Nottingham, NG7 2UH, UK; robin.spiller{at}nottingham.ac.uk
Citation
A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D)
Publication history
- Received January 6, 2015
- Revised February 2, 2015
- Accepted February 3, 2015
- First published March 12, 2015.
Online issue publication
April 18, 2016
Article Versions
- Previous version (18 April 2016).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Files in this Data Supplement:
- Data supplement 1 - Online supplement
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/